CBS 2019
CBSMD教育中心
中 文

动脉粥样硬化性心血管疾病

Abstract

Recommended Article

Long-term effects of intensive glucose lowering on cardiovascular outcomes Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies Simple Electrocardiographic Measures Improve Sudden Arrhythmic Death Prediction in Coronary Disease Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Consensusolume 41, Issue 24, 21 June 2020, Pages 2313–2330

JOURNAL:Eur Heart J. Article Link

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

J Borén, MJ Chapman, RM Krauss et al. Keywords: low-density lipoprotein; ASCVD; statin; mechanisms

Full Text PDF